216 related articles for article (PubMed ID: 1385867)
1. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
[TBL] [Abstract][Full Text] [Related]
2. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.
Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA
Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons.
Cadroy Y; Maraganore JM; Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1177-81. PubMed ID: 1996320
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.
Yokoyama T; Kelly AB; Marzec UM; Hanson SR; Kunitada S; Harker LA
Circulation; 1995 Aug; 92(3):485-91. PubMed ID: 7634464
[TBL] [Abstract][Full Text] [Related]
5. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
Cadroy Y; Houghten RA; Hanson SR
J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.
Gruber A; Harker LA; Hanson SR; Kelly AB; Griffin JH
Circulation; 1991 Dec; 84(6):2454-62. PubMed ID: 1835678
[TBL] [Abstract][Full Text] [Related]
7. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons.
Lumsden AB; Kelly AB; Schneider PA; Krupski WC; Dodson T; Hanson SR; Harker LA
Blood; 1993 Apr; 81(7):1762-70. PubMed ID: 8461462
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts.
Oltrona L; Eisenberg PR; Abendschein DR; Rubin BG
J Vasc Surg; 1996 Oct; 24(4):624-31. PubMed ID: 8911411
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.
Hanson SR; Griffin JH; Harker LA; Kelly AB; Esmon CT; Gruber A
J Clin Invest; 1993 Oct; 92(4):2003-12. PubMed ID: 8408654
[TBL] [Abstract][Full Text] [Related]
10. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
11. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates.
Cadroy Y; Hanson SR; Kelly AB; Marzec UM; Evatt BL; Kunicki TJ; Montgomery RR; Harker LA
Blood; 1994 Jun; 83(11):3218-24. PubMed ID: 8193356
[TBL] [Abstract][Full Text] [Related]
12. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
[TBL] [Abstract][Full Text] [Related]
13. Strategies for inhibiting the effects of thrombin.
Harker LA
Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S47-58; discussion S59-64. PubMed ID: 8186356
[TBL] [Abstract][Full Text] [Related]
14. Allosteric changes in thrombin's activity produced by peptides corresponding to segments of natural inhibitors and substrates.
Hortin GL; Trimpe BL
J Biol Chem; 1991 Apr; 266(11):6866-71. PubMed ID: 1849894
[TBL] [Abstract][Full Text] [Related]
15. A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons.
Kotzé HF; Lamprecht S; Badenhorst PN
Blood; 1995 Jun; 85(11):3158-63. PubMed ID: 7756648
[TBL] [Abstract][Full Text] [Related]
16. Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates.
Cadroy Y; Hanson SR; Harker LA
Arterioscler Thromb; 1993 Aug; 13(8):1213-7. PubMed ID: 8343496
[TBL] [Abstract][Full Text] [Related]
17. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1988 May; 85(9):3184-8. PubMed ID: 3362867
[TBL] [Abstract][Full Text] [Related]
18. Role of the thrombin insertion loop 144-155. Study of thrombin mutations W148G, K154E and a thrombin-based synthetic peptide.
Bouton MC; Plantier JL; Dembak M; Guillin MC; Rabiet MJ; Jandrot-Perrus M
Eur J Biochem; 1995 Apr; 229(2):526-32. PubMed ID: 7744076
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.
Cadroy Y; Hanson SR; Harker LA
Thromb Haemost; 1993 Oct; 70(4):631-5. PubMed ID: 8115989
[TBL] [Abstract][Full Text] [Related]
20. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors.
Dichek DA; Anderson J; Kelly AB; Hanson SR; Harker LA
Circulation; 1996 Jan; 93(2):301-9. PubMed ID: 8548903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
